ライフサイエンスコーパス: dual therapy

1 antibody compromised the survival benefit of dual therapy.

2 udes a protease inhibitor than with standard dual therapy.

3 to continue taking prednisone and tacrolimus dual therapy.

4 reatment, and 0.49 (0.31-0.79) compared with dual therapy.

5 similar in both groups (monotherapy, 62.5%; dual therapy, 68.4%; P = 0.694).

6 ted with a higher likelihood of SVR than was dual therapy (absolute difference, 22 to 31 percentage p

7 Compared with standard dual therapy, addition of aprepitant was generally well

8 hly active combination therapy or 1 month of dual therapy after SD-NVP prevents most NVP resistance t

9 d TGF-beta1 may provide useful targets for a dual therapy aimed at slowing disease progression in Alp

10 Dual therapy also led to changes in tumor-associated mac

11 3,030 patients) of drugs added to metformin (dual therapy); and 29 trials (10,598 patients) of drugs

12 00 person-years of follow-up for patients on dual therapy, and 3.4 per 100 person-years of follow-up

13 Four participants in the dual-therapy arm and 2 in the triple-therapy arm develop

14 serious adverse events occurred, both in the dual-therapy arm, one of which (a case of gastritis) was

15 Neither dabigatran 110 mg nor dual therapy (aspirin and clopidogrel) was cost-effectiv

16 n of latanoprost and timolol or eligible for dual therapy being not being fully controlled on monothe

17 Compared with dual therapy, boceprevir triple therapy increased risk f

18 tential for metformin and estrogen-progestin dual therapy but warrant longitudinal studies examining

19 experimental/modeling approach suggest that dual therapy can be more efficacious than single therapi

20 Dual therapy consisted of lopinavir 400 mg and ritonavir

21 more effective than peginterferon-ribavirin dual therapy (DT) in the treatment of previously untreat

22 with their vascular-modulating function, the dual therapies enhanced morphological normalization of v

23 ular disease), however, the bleeding risk of dual therapy exceeds its potential benefit.

24 sult of disease reactivation, whereas 50% of dual-therapy failures were the result of drug intoleranc

25 For genotype 2 or 3 infection, dual therapy for 12 to 16 weeks was associated with a lo

26 ndomly assigned after week 20 to receive the dual therapy for 4 more weeks (T12PR24) or 28 more weeks

27 sponse rates in HCV-infected women receiving dual therapy for HCV infection, this seems to be less im

28 erlotinib and IL36alpha siRNA as a potential dual therapy for psoriasis.

29 ange in VA for monotherapy compared with the dual therapy group was less than 1 logMAR letter (logMAR

30 iple-therapy group (n=10 [4.9%]) than in the dual-therapy group (n=1 [0.4%]; difference 4.5%, 95% CI

31 At week 48, 189 patients (88.3%) in the dual-therapy group and 169 (83.7%) in the triple-therapy

32 198 patients in the dual-therapy group and 175 in the triple-therapy group c

33 , 217 patients were randomly assigned to the dual-therapy group and 209 to the triple-therapy group.

34 65 adverse events in the dual-therapy group and 88 in the triple-therapy group we

35 1.4% (95% CI, 31.6 to 78.2; P=0.0013) in the dual-therapy group at day 7 and by 61.6% (95% CI, 34.9 t

36 apy group versus no stroke and 4 TIAs in the dual-therapy group that were treatment emergent and ipsi

37 Triple and dual therapies had an observable trend ((186)Re-liposoma

38 In response to dideoxy inosine/hydroxyurea dual therapy, HIV-1 (human immunodeficiency virus type-1

39 to 55%) with TH (P = .13), with no effect of dual therapy in the hormone receptor-positive subset but

40 10 mg prednisone daily, and any advantage of dual therapy in the prevention of disease reactivation w

41 ubset but a significant increase in pCR with dual therapy in those with hormone receptor-negative dis

42 for the use of triple therapy compared with dual therapy in treatment of both naive individuals and

43 confidence interval [CI]: 1.40 to 1.68) and dual-therapy (IRR: 1.22; 95% CI: 1.06 to 1.40).

44 th ASA (IRR: 2.00; 95% CI: 1.88 to 2.12) and dual-therapy (IRR: 1.30; 95% CI: 1.18 to 1.43).

45 e bleeding risk was significantly higher for dual-therapy (IRR: 1.93; 95% CI: 1.81 to 2.07).

46 Dual therapy is now obsolete.

47 e United States with the current recommended dual therapy one step closer.

48 Systematic reviews and randomized trials of dual therapy or monotherapy with 1 or more of the preced

49 Patients were randomly assigned (1:1) to dual therapy or triple therapy by sealed envelopes, in b

50 tions between any drug class as monotherapy, dual therapy, or triple therapy with odds of cardiovascu

51 reduction in the primary end point: 43.8% of dual-therapy patients were MES positive on day 7, as com

52 Importantly, dual therapy promotes reductions in AD pathology and res

53 The dual therapy reduces PD-L1(+) cells and facilitates non-

54 to incorporate phage and antibiotics into a dual therapy regimen; however, this increases the comple

55 We found that dual-therapy rescued inflammation and fibrosis, improved

56 We find that dual therapy results in long-term disease control for mo

57 ed the role of metformin as a monotherapy or dual therapy supplement and found significant benefit wh

58 Dual therapy using cediranib and MEDI3617 (an anti-Ang-2

59 acid (ASA) monotherapy and 8,962 (13%) with dual-therapy (VKA + ASA).

60 .97) and in 0.8% (1/126) vs 1.6% P = .55) in dual therapy vs triple therapy, respectively.

61 Switching to dual therapy was associated with a significant increase

62 Dual therapy was classed as non-inferior to triple thera

63 ute noncardioembolic ischemic stroke or TIA, dual therapy was more effective than monotherapy in redu

64 tibacterial activity of this macrolide since dual therapy with ampicillin and azithromycin against an

65 In this retrospective study, dual therapy with an oral third-generation cephalosporin

66 relation between platelet reactivity during dual therapy with aspirin and clopidogrel and clinical o

67 ol and Prevention (CDC) currently recommends dual therapy with ceftriaxone and azithromycin for gonor

68 idence from randomized trials indicates that dual therapy with clopidogrel and aspirin is modestly bu

69 to assess the therapeutic noninferiority of dual therapy with darunavir/ritonavir and lamivudine com

70 Dual therapy with darunavir/ritonavir and lamivudine dem

71 Pilot studies are evaluating the efficacy of dual therapy with dolutegravir (DTG) and lamivudine (3TC

72 for pharyngeal gonorrhea treatment recommend dual therapy with intramuscular ceftriaxone and either a

73 Dual therapy with lopinavir and ritonavir plus lamivudin

74 We investigated whether dual therapy with lopinavir and ritonavir plus lamivudin

75 gen IV accumulation) benefits were seen upon dual therapy with metformin.

76 ansplant recipients can be safely reduced to dual therapy with MMF or CNIs, applying concentration-co

77 Dual therapy with P1pal-7 and Taxotere inhibits the grow

78 for 12 weeks, followed by 12 or 36 weeks of dual therapy with PEG-IFN and RBV.

79 Dual therapy with pegylated interferon alfa-2b plus riba

80 After treatment with ceftriaxone mono- or dual therapy (with azithromycin or doxycycline), anal, v